These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 18562408)

  • 21. [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
    Fric M; Laux G
    Psychiatr Prax; 2003 May; 30 Suppl 2():S97-101. PubMed ID: 14509051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
    Tschoner A; Engl J; Rettenbacher MA; Kaser S; Ott HW; Fleischhacker WW; Patsch JR; Ebenbichler CF
    J Clin Psychiatry; 2009 Feb; 70(2):293-4. PubMed ID: 19265646
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
    Papadimitriou GN; Theleritis CG; Dikeos DG; Psarros CJ; Soldatos CR
    Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density.
    Stubbs B
    J Psychiatr Ment Health Nurs; 2009 Nov; 16(9):838-42. PubMed ID: 19824978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M; Scheel T; Eich FX
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients].
    Konarzewska B; Szulc A; Popławska R; Galińska B; Juchnowicz D
    Psychiatr Pol; 2008; 42(1):87-95. PubMed ID: 18567406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
    Byerly M; Suppes T; Tran QV; Baker RA
    J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic medication and marked hyperprolactinaemia: iatros or true prolactinoma?
    Koves IH; Jarman FC; Cameron FJ
    Acta Paediatr; 2004 Nov; 93(11):1543-7. PubMed ID: 15513588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey.
    Johnsen E; Kroken RA; Abaza M; Olberg H; Jørgensen HA
    J Clin Psychopharmacol; 2008 Dec; 28(6):686-90. PubMed ID: 19011438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperprolactinaemia with amisulpride.
    Ružić K; Grahovac T; Graovac M; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
    Psychiatr Danub; 2011 Mar; 23(1):92-4. PubMed ID: 21448106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sexual dysfunction in schizophrenia: focus on recent evidence.
    Baggaley M
    Hum Psychopharmacol; 2008 Apr; 23(3):201-9. PubMed ID: 18338766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.
    Rad F; Buica AM; Anghel GC; Stancu M; Dobrescu I
    Riv Psichiatr; 2019; 54(1):37-39. PubMed ID: 30760936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics.
    Liu-Seifert H; Kinon BJ; Ahl J; Lamberson S
    Ann N Y Acad Sci; 2004 Dec; 1032():297-8. PubMed ID: 15677434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight gain in a patient with schizophrenia switched from quetiapine to amisulpride.
    Chen YY; Huang MC; Wu KC
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):620-1. PubMed ID: 18950385
    [No Abstract]   [Full Text] [Related]  

  • 40. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
    Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
    J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.